India Extends Medical Device PLI Scheme Through 2036
Recently, the Department of Pharmaceuticals extended the medical device PLI scheme up to fiscal year 2036. This revised framework, known as PLI-MD 2.0, unlocks an available outlay of roughly Rs 2,700 crore. Consequently, medical technology manufacturers will gain access to simplified eligibility norms and wider funding pathways. In addition, the central government removed earlier operational bottlenecks to accelerate the production of high-value clinical hardware.
Key Overhauls in the Medical Device PLI Scheme
Most notably, the ministry discontinued the minimum sales threshold requirement to claim financial payouts. Previously, rigid revenue benchmarks disqualified several emerging companies from claiming incentives. Furthermore, authorities lowered the baseline investment requirement to attract smaller manufacturers and startups. Under the updated scheme, applicants will receive a three-year window to establish greenfield or brownfield units. Therefore, firms can scale their production lines without facing unrealistic initial deadlines. Meanwhile, an open online application portal will go live within ten days to receive fresh proposals.
Target Segments and Production Incentives
Specifically, the updated policy organizes support across four distinct target categories. The first segment encompasses essential medical consumables, disposables, and surgical implants. Additionally, the second category focuses heavily on indigenous critical components like X-ray tubes and specialized detectors. The remaining categories target nascent domestic manufacturing and assembly of sophisticated capital equipment. For instance, average incentive rates will range between 5% for consumables to 9% for critical diagnostic equipment. Consequently, this tiered approach encourages deep local value addition rather than basic assembly.
Clinical and Healthcare Implications for Doctors
For Indian clinicians, local manufacturing directly impacts the availability and cost of advanced hospital technology. In fact, the first phase already generated over Rs 16,000 crore worth of domestic medical devices. These milestones included domestic 1.5T MRI scanners, linear accelerators, mammography units, and specialized dialyzers. However, India still imports major high-end systems such as 3T MRI machines and PET-CT scanners. As a result, robust domestic manufacturing will reduce procurement costs and shorten equipment lead times for hospitals. Moreover, self-reliant component supply chains safeguard intensive care units against international disruptions.
Frequently Asked Questions
Q1: What is the main objective of PLI-MD 2.0?
The updated initiative aims to foster deep domestic manufacturing of complex medical devices and critical components across India.
Q2: Which major entry barriers did the government remove?
The authorities eliminated the minimum sales threshold to claim incentives and reduced the minimum mandatory capital investment requirement.
Q3: How long will the medical device PLI scheme remain active?
The revised policy framework extends the operational timeline of the incentive programme through financial year 2035–2036.
References
- Centre extends medical device PLI Scheme to 2036, eases entry barriers - ETHealthworld
- Fresh applications invited under PLI Scheme for Medical Devices - Press Information Bureau
- Medical device PLI scheme extended by 8 years; focus shifts to components - Business Standard
